Psagot Value Holdings’s Protalix BioTherapeutics PLX Stock Holding History

Psagot Value Holdings’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,744	Closed	-$7K	–	599
2023 Q1	$7K	Sell	3,744 -2,256	-38%	-$3.96K	﹤0.01%	312
2022 Q4	$8K	Hold	6,000	–	–	﹤0.01%	328
2022 Q3	$6K	Hold	6,000	–	–	﹤0.01%	318
2022 Q2	$7K	Hold	6,000	–	–	﹤0.01%	273
2022 Q1	$6K	Hold	6,000	–	–	﹤0.01%	299
2021 Q4	$5K	Hold	6,000	–	–	﹤0.01%	329
2021 Q3	$8K	Hold	6,000	–	–	﹤0.01%	375
2021 Q2	$11K	Sell	6,000 -3,089,741	-100%	-$10.6M	﹤0.01%	397
2021 Q1	$13.8M	Buy	3,095,741 +2,625,486	+558%	+$12.2M	0.31%	83
2020 Q4	$1.71M	Hold	470,255	–	–	0.04%	149
2020 Q3	$1.82M	Hold	470,255	–	–	0.05%	132
2020 Q2	$1.73M	Buy	470,255 +63,900	+16%	+$218K	0.05%	120
2020 Q1	$955K	Buy	406,355 +406,255	+406,255%	+$1.34M	0.04%	138
2019 Q4	$0	Hold	100	–	–	﹤0.01%	457
2019 Q3	$0	Hold	100	–	–	﹤0.01%	423
2019 Q2	$0	Sell	100 -3,036	-97%	-$12.8K	﹤0.01%	443
2019 Q1	$14K	Sell	3,136 -31	-1%	-$140	﹤0.01%	403
2018 Q4	$10K	Buy	3,167 +118	+4%	+$561	﹤0.01%	403
2018 Q3	$22K	Sell	3,049 -45	-1%	-$226	﹤0.01%	327
2018 Q2	$13K	Buy	3,094 +165	+6%	+$733	﹤0.01%	309
2018 Q1	$15K	Buy	2,929 +10	+0.3%	+$66	﹤0.01%	306
2017 Q4	$20K	Sell	2,919 -339	-10%	-$2.29K	﹤0.01%	266
2017 Q3	$19K	Buy	3,258 +91	+3%	+$583	﹤0.01%	285
2017 Q2	$26K	Buy	3,167 +962	+44%	+$9.03K	﹤0.01%	275
2017 Q1	$30K	Sell	2,205 -20	-0.9%	-$180	﹤0.01%	289
2016 Q4	$10K	Buy	2,225 +20	+0.9%	+$89	﹤0.01%	307
2016 Q3	$13K	Hold	2,205	–	–	﹤0.01%	304
2016 Q2	$14K	Sell	2,205 -6,319	-74%	-$50.5K	﹤0.01%	287
2016 Q1	$72K	Sell	8,524 -1,664	-16%	-$14.3K	﹤0.01%	290
2015 Q4	$103K	Buy	10,188 +1,478	+17%	+$15K	﹤0.01%	287
2015 Q3	$103K	Sell	8,710 -3,540	-29%	-$56.3K	﹤0.01%	281
2015 Q2	$239K	Buy	12,250 +5,057	+70%	+$105K	0.01%	237
2015 Q1	$128K	Hold	7,193	–	–	﹤0.01%	272
2014 Q4	$132K	Hold	7,193	–	–	﹤0.01%	279
2014 Q3	$174K	Hold	7,193	–	–	0.01%	233
2014 Q2	$263K	Hold	7,193	–	–	0.01%	207
2014 Q1	$329K	Sell	7,193 -255	-3%	-$11.9K	0.01%	221
2013 Q4	$290K	Buy	7,448 +4,987	+203%	+$210K	0.01%	243
2013 Q3	$111K	Hold	2,461	–	–	﹤0.01%	327
2013 Q2	$121K	Buy	+2,461	New	+$131K	0.01%	239

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Psagot Value Holdings's PLX Position: Q2 2023 in Review

Psagot Value Holdings sold out of Protalix BioTherapeutics (PLX) in Q2 2023, closing a stake of 3,744 shares — an estimated $7K sold.

Psagot Value Holdings first reported a position in PLX in Q2 2013 and held it in 40 quarters. The position peaked at $13.8M in Q1 2021. 66 funds tracked by Wall St. Rank hold PLX as of Q2 2023.

Psagot Value Holdings reported no remaining Protalix BioTherapeutics position as of Q2 2023 after selling out during the quarter.
Psagot Value Holdings sold 3,744 Protalix BioTherapeutics shares in Q2 2023, an estimated $7K.
Psagot Value Holdings first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 40 quarters.
Psagot Value Holdings's Protalix BioTherapeutics position peaked at $13.8M in Q1 2021.
66 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2023.

Based on Psagot Value Holdings's 13F filing for Q2 2023, filed 3 Aug 2023.